Catalent (CTLT) Getting Somewhat Favorable News Coverage, Accern Reports

News stories about Catalent (NYSE:CTLT) have been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Catalent earned a news impact score of 0.13 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.1850793346204 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:

A number of equities research analysts have issued reports on the stock. Royal Bank of Canada set a $48.00 price objective on shares of Catalent and gave the stock a “buy” rating in a research note on Monday, February 5th. Stephens downgraded shares of Catalent from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, February 6th. ValuEngine upgraded shares of Catalent from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th. Zacks Investment Research upgraded shares of Catalent from a “hold” rating to a “buy” rating and set a $48.00 price target on the stock in a research note on Monday, November 6th. Finally, BidaskClub downgraded shares of Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Catalent presently has a consensus rating of “Buy” and a consensus target price of $45.60.

Shares of Catalent (CTLT) traded up $1.29 during midday trading on Thursday, reaching $42.87. 1,591,597 shares of the company were exchanged, compared to its average volume of 968,601. The company has a market cap of $5,700.00, a price-to-earnings ratio of 77.95, a PEG ratio of 2.34 and a beta of 1.47. Catalent has a 1-year low of $27.48 and a 1-year high of $47.87. The company has a current ratio of 2.22, a quick ratio of 1.78 and a debt-to-equity ratio of 2.66.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The business had revenue of $606.30 million during the quarter, compared to analyst estimates of $565.05 million. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The firm’s quarterly revenue was up 25.3% on a year-over-year basis. During the same quarter last year, the business earned $0.27 EPS. analysts predict that Catalent will post 1.53 EPS for the current year.

In other Catalent news, Director Uwe Roehrhoff acquired 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was acquired at an average price of $39.22 per share, for a total transaction of $294,150.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total transaction of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Catalent (CTLT) Getting Somewhat Favorable News Coverage, Accern Reports” was posted by BBNS and is the property of of BBNS. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://baseballnewssource.com/markets/catalent-ctlt-getting-somewhat-favorable-news-coverage-accern-reports/1884831.html.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Insider Buying and Selling by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August
Mookie Betts Awarded Arbitration of $10.5 Million
Mookie Betts Awarded Arbitration of $10.5 Million
Alex Cora Leading Effort by Red Sox to Deliver Puerto Rico Relief Supplies
Alex Cora Leading Effort by Red Sox to Deliver Puerto Rico Relief Supplies


Leave a Reply

 
© 2006-2018 BBNS.